Vetr Upgrades Juno To Buy Amid Volatile May

The Vetr crowd on Monday upgraded its rating for Juno Therapeutics Inc (NASDAQ:JUNO) from 4 stars, issued two days ago, to 5 stars. Crowd sentiment at the time of the upgrade was mostly positive, with 87 percent of Vetr user ratings bullish.

Price in the oncology-centered biotech company has been extremely active throughout the month of May, spiking and correcting rapidly by as much as 15 percent several times over the month. The first correction that dropped the stock about $3.50 followed a mixed earnings report on May 4 that showed higher-than-expected sales, but EPS that matched low expectations. The stock quickly rebounded and surpassed its per-earnings price, rising above $26 by mid-May. Still, stock has receded somewhat since then, closing Monday at $24.07.


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!


27% profit every 20 days?

This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.


Learn how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average target price for Juno is up at $27.94, which is still below the average analyst target price of $34.50. Less than 2 percent of Vetr users are holding JUNO in their watch lists.

Posted In: UpgradesPrice TargetCrowdsourcingAnalyst RatingsVetr